MIST
Milestone Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$0.70
−1.02%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$0.71
From 52W high−76.27%
Volume663443.00
Market cap$87.16M
P/E (TTM)—
P/S (TTM)37.2x
Div yield—
Key dataOct 19, 2026
Open
$0.71
From 52W high
−76.27%
Volume
663443.00
Market cap
$87.16M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.8x
P/E (TTM)
—
RSI (14)
34.1
MomentumView details →
1D Return
−1.02%
YTD Return
−64.88%
SummaryUpdated Jun 1, 2026
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) is a Canadian biopharmaceutical company founded in 2003 and headquartered in Montréal. The company went public in May 2019 and focuses exclusively on developing cardiovascular medicines for patients with heart rhythm disorders. Milestone is currently a clinical-stage company with no approved products on the market, dedicating its resources to advancing its lead drug candidate etripamil through late-stage clinical trials for treating specific types of rapid heart rhythm conditions.
Similar companies
Latest newsMore news →
Milestone Pharmaceuticals announced that data and program updates on CARDAMYST (etripamil) nasal spray will be presented at three upcoming cardiovascular medical meetings.10h agoMilestone Pharmaceuticals Inc. announced that the first European participant had enrolled in its ReVeRA-301 Phase 3 trial evaluating etripamil nasal spray for AFib-RVR, with the Dutch Cardiovascular Investigator Network leading European enrollment.10d agoMilestone Pharmaceuticals announced that the Montreal Heart Institute, the first activated Canadian site for the ReVeRA-301 Phase 3 pivotal trial, enrolled its first patient in the trial evaluating etripamil nasal spray for atrial fibrillation with rapid ventricular rate.25d ago